High Dose Chemotherapy and Hematopoietic Progenitor Cell Transplantation for Breast Cancer

Pedrazzoli, Paolo; Tarenzi, Emiliana; Tullio, C.; Colosini, Giuseppe; Siena, Salvatore

doi:10.1179/joc.2004.16.supplement-1.108

Cited by 5 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 In addition, because of the heterogeneity of intensity and duration of the standard dose chemotherapy (SDC) in the control arm, the outcomes of these studies have been quite variable. 17 As a contribution to the ongoing discussion on HDC for BC we report here the results of this therapeutic approach in almost 6000 women receiving ASCT at 370 European Group for Blood and Marrow Transplantation (EBMT) centers between 1990 and 1999.…”

Section: Discussionmentioning

confidence: 99%

“…Highs and lows in the enthusiasm for HDC in BC has been largely unreasonable since no definitive conclusions can be drawn despite a huge number of studies reported throughout the last two decades. 16,17 This has cast a pall over the entire field and has resulted in both a low accrual of early prospective trials (irrational exuberance phase) and a moratorium on new studies (reticence phase). The EBMT Registry data confirm that HDC with ASCT today is a safe procedure.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990–1999

Pedrazzoli

Ferrante

Kulekci³

et al. 2003

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:The aim of this study was to identify trends in high-dose chemotherapy (HDC) with autologous hematopoietic stem cell transplantation (ASCT) and to assess survival in a large cohort of breast cancer (BC) patients receiving this therapy in Europe from 1990 to 1999. A total of 7471 patients who received HDC with ASCT between January 1, 1990 and December 31, 1999 were reported to the European Group for Blood and Marrow Transplantation Registry. Data required for demographics and survival analysis were available for 2679 patients with high-risk primary BC; 921 patients with inflammatory BC (IBC), and 2295 patients with metastatic disease. The main evaluation parameters were progression-free survival (PFS) and overall survival (OS). Between 1990 and 1998, autotransplants for BC increased 30-fold. Significant trends included use of blood-derived rather than marrow-derived stem cells, increment of reporting centers and decrease of mortality within 100 days from transplantation. The 5-year PFS and OS probabilities were 53 and 68% for high-risk disease and 42 and 53% for IBC, respectively. For metastatic disease 5-year PFS and OS probabilities in the whole cohort were 18 and 27%, respectively, while for women transplanted in complete remission the 5-year PFS was 29%. In conclusion, HDC with ASCT has been increasingly used until 1998 and the 100-day mortality rate has been constantly less than 2% from 1995 to date. The 5-year survival of high-risk BC is related to the number of axillary nodes involved at surgery. Outcome of patients with IBC is encouraging, suggesting the need for randomized trials. Patients with metastatic disease responding to pretransplant chemotherapy and harboring ER+ tumors have a better outcome.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990–1999

Pedrazzoli

Ferrante

Kulekci³

et al. 2003

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…The expanding indications of high‐dose therapy (HDT) in hematologic 1,2 and nonhematologic malignancies 3 are associated with an increasing request for simplification and cost reduction of routine freezing procedures.…”

mentioning

confidence: 99%

Long‐term hematologic reconstitution after autologous peripheral blood progenitor cell transplantation: a comparison between controlled‐rate freezing and uncontrolled‐rate freezing at 80°C

Montanari¹,

Capelli²,

Poloni³

et al. 2003

Transfusion

View full text Add to dashboard Cite

show abstract

“…MITO-MEL schedule was the final part of two HDC programs (GOCAM RC study 1 and 2) ( Figure 1), including an induction phase with three courses of conventional chemotherapy with epirubicin (120 mg/m 2 ) and cyclophosphamide (600 mg/m 2 ) (EPI-CTX) ±three courses of docetaxel (100 mg/m 2 ) (DTX) and a first HDC consisting of cyclophosphamide (CTX) (6000 mg/m 2 ), thiotepa (THI) (500 mg/m 2 ) and carboplatin (CBP) (800 mg/m 2 ) or MEL (160 mg/m 2 ) plus THI (600 mg/m 2 ). PBSC were collected following the EPI-CTX chemotherapy.…”

Section: Patient Characteristics and Hdcmentioning

confidence: 99%

High-Dose Chemotherapy with Mitoxantrone + Melphalan and Autologous Stem Cell Rescue in Metastatic Breast Cancer Patients: A Study of Feasibility and Tolerability

Martino

Morabito

Console

et al. 2003

Tumori

View full text Add to dashboard Cite

Hematological and extra-hematological toxicity of mitoxantrone-containing regimens with autologous stem cell rescue was evaluated in 32 metastatic breast cancer patients. The schedule was the final part of two high-dose chemotherapy programs, including an induction phase with three courses of conventional chemotherapy with epirubicin (120 mg/m2) and cyclophosphamide (600 mg/m2) plus three courses of docetaxel (100 mg/m2) and a first high-dose chemotherapy consisting of cyclophosphamide (6000 mg/m2), thiotepa (500 mg/m2) and carboplatin (800 mg/m2) or melphalan (160 mg/m2) plus thiotepa (600 mg/m2). The final second autograft phase included mitoxantrone (60 mg/m2) associated with melphalan (160 mg/m2) and autologous stem cell rescue infusion. The median duration of severe neutropenia and thrombocytopenia was 9 (range, 7-13) and 11.5 (range, 9-29) days. The median number of units of erythrocytes and platelets transfused was 1 (0-11) and 4 (1-9), respectively. Fever for a median of 2 (0-8) days developed in 71.8% of the patients. Mucositis was observed in 81.2% (WHO grade 3-4 in 25%). No acute or late cardiac toxicity was observed. One patient died because of a transplant-unrelated cause. The response according to the program phase showed an increased rate of complete response, from 12.5% at the end of conventional chemotherapy to 21.9% after the first high-dose chemotherapy course, to increase to 43.9% after the treatment with mitoxantrone-melphalan. We conclude that a conditioning regimen with high dose mitoxantrone-melphalan fits well within the high-dose chemotherapy program.

show abstract

High Dose Chemotherapy and Hematopoietic Progenitor Cell Transplantation for Breast Cancer

Cited by 5 publications

References 17 publications

Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990–1999

Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990–1999

Long‐term hematologic reconstitution after autologous peripheral blood progenitor cell transplantation: a comparison between controlled‐rate freezing and uncontrolled‐rate freezing at 80°C

High-Dose Chemotherapy with Mitoxantrone + Melphalan and Autologous Stem Cell Rescue in Metastatic Breast Cancer Patients: A Study of Feasibility and Tolerability

Contact Info

Product

Resources

About